Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) saw an uptick in trading volume on Thursday . 1,700,768 shares were traded during trading, a decline of 27% from the previous session’s volume of 2,343,552 shares.The stock last traded at $4.90 and had previously closed at $5.10.
Several research firms recently issued reports on HTGM. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of HTG Molecular Diagnostics in a research report on Thursday, February 1st. Zacks Investment Research lowered HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday, January 26th. Finally, Canaccord Genuity raised their price target on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. HTG Molecular Diagnostics presently has a consensus rating of “Hold” and an average price target of $5.31.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after acquiring an additional 37,841 shares during the last quarter. Granahan Investment Management Inc. MA grew its position in HTG Molecular Diagnostics by 488.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 416,608 shares of the medical research company’s stock worth $708,000 after acquiring an additional 345,798 shares during the last quarter. Finally, Private Wealth Partners LLC bought a new position in HTG Molecular Diagnostics during the 4th quarter worth approximately $710,000. Institutional investors and hedge funds own 7.96% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.